Christian Weyer

Biography

Christian Weyer, M.D., M.A.S. has served as our Executive Vice President of Research & Development since November of 2017. Dr. Weyer’s career in metabolic drug development spans more than 20 years, involving clinical studies and regulatory submissions at all stages of product development and across the continuum of diabetes, obesity and NAFLD/NASH. Prior to joining Intercept, Dr. Weyer was President and Chief Development Officer at ProSciento, a leading clinical R&D service provider focused on diabetes, NAFLD/NASH and obesity. Dr. Weyer has served as a senior executive in several companies, including as Chief Executive Officer of Fate Therapeutics, where he steered the company’s transition into a publicly-traded cellular therapeutics company, and as Senior Vice President of R&D at Amylin Pharmaceuticals, where he contributed to the development and approval of several first-in-class medicines for diabetes and lipodystrophy.  Before joining Amylin, Dr. Weyer worked at the National Institutes of Health, NIDDK, conducting clinical research on the pathogenesis of obesity and type 2 diabetes.  Dr. Weyer received his M.D. and clinical training at the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf, Germany and holds a postdoctoral master’s degree in advanced clinical research from the University of California, San Diego. 

Research Interest

Pharmaceutical Sciences